West Pharmaceutical Services, Inc. (NYSE: WST) — A Toll Booth on Every Injectable, Recovered and Priced for It

Report date: June 21, 2026 Price (as of 2026-06-18 close): ~$327.95/share Market cap: ~$23.0B · Enterprise value (live recompute): ~$22.4B · Net cash: ~$588M · Shares: ~72.0M Sector / classification: Health Care → Life Sciences Tools & Services → Injectable Drug Containment & Delivery Components CIK: 0000105770 · HQ: Exton, Pennsylvania · FY-end: December 31 · Founded: 1923

The body of this article (Executive Summary onward) is written to be position-free and carries no investment recommendation and no price target. The single, deliberately fenced-off exception is the Author’s Take block immediately below, which is a subjective view.

⚡ Author’s Take

This block is the author’s own subjective opinion. It is general information and not investment advice. Everything from the Executive Summary onward is position-free and carries no price target except where this block is quoted.

Verdict: HOLD — a genuinely wonderful franchise at a full fare. Own quality here but demand a discount: accumulate-on-weakness in the ~$240–280 zone (≈30x forward earnings, where the GLP-1/Annex-1 optionality stops being free), with a high-conviction destock-style washout entry at ~$190–230. NOT a short. Conviction: medium.

Tag: “The drug-master-file moat — recovered, re-accelerating, and priced for all of it.”

West Pharmaceutical is one of the best businesses in healthcare hiding behind one of its most boring products: the rubber stopper, seal, and plunger that touch the drug inside every injectable vial and prefilled syringe. The moat is the real thing — Greenwald demand-captivity through regulatory switching costs. Once a West component is written into a customer’s drug master file and validated in stability and compatibility studies, switching means re-qualification and a regulatory refiling — years of work and risk — for the life of the drug. That lock-in shows up in the numbers that matter: gross margins of 35–41% across the cycle, a return on invested capital that has cleared its cost of capital every single year (peaking near 26%), a net-cash balance sheet built organically (just $110M of goodwill — this is a plant-builder, not a levered roll-up), and a compensation plan that — rare among the names I cover — actually carries a real ROIC governor (the 2023–25 performance shares paid only 41%). It is riding three genuine secular tailwinds: the shift to biologics, the Annex 1 regulation that mechanically converts low-margin standard components into high-margin ones (a ~6-billion-unit, multi-year, +200bps-a-year escalator that is <15% complete), and GLP-1 injectables. After over-earning spectacularly during COVID (vaccine vials drove EPS to $8.67 in 2021) and then enduring a brutal customer-destocking bust (EPS fell to $6.69 by 2024, the stock crashed ~60% to a $189 trough in early 2025), the franchise is re-accelerating hard — Q1-2026 organic growth +15.3%, high-value components +22.6%, biologics +26%, and management raised the full-year guide to +15–20% adjusted EPS.

Here is my problem: the market already knows all of this. The stock has rallied +51% over the past twelve months to ~$328 and trades at ~38x the raised FY26 guide / ~45x trailing adjusted earnings / ~27x EV/EBITDA — the highest multiple in its entire peer cohort (versus best-quality tools names at 20–22x EV/EBITDA and direct pharma-packaging comps Stevanato/AptarGroup at ~12x), on a ~2% real free-cash-flow yield (true FCF, not the OCF the screens mislabel — West is still digesting a ~$1.3B capacity build that dragged ROIC from 26% to 15%). A reverse-DCF says the price requires a sustained ~14% FCF compound for a decade — i.e., the full return-to-the-double-digit-algorithm is the base case in the price, leaving zero valuation cushion. That is the whole trade: this is no longer a falling knife or a mean-reversion bounce (the COVID round-trip is fully unwound; 3- and 5-year returns are flat-to-negative), it is a pure earnings-compounding bet at a premium multiple where re-rating and yield contribute nothing and a single growth wobble compresses you toward the peers’ 20x. The bull case (GM back to 40%, ROIC re-leveraging to 20%+, GLP-1 plus Annex-1 plus biologics compounding low-teens EPS) is plausible and I’d happily own it — at a price that pays me to wait for the execution rather than asking me to pre-fund it. Flip me bullish: a meaningful de-rate into the ~$250s with the re-acceleration intact, or three to four quarters of a clean margin march back toward 40% gross that proves the algorithm is structural, not a destock-bounce. Flip me bearish: the top customer (now 15.8% of sales and climbing, almost certainly a large GLP-1 maker) stumbles, oral GLP-1 substitution runs ahead of the >30%-by-2030 the guide embeds, or the margin recovery stalls near 36% — any of which, with no cushion and a new CEO (ex-Thermo Fisher’s Michel Lagarde, in the chair from Aug 31) at the controls, de-rates a 38x stock fast.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are FACT; attributed causes are INTERPRETATION.

The arc. West round-tripped a COVID bubble. From ~$280 in early 2020 it ran ~60% to a $465.70 all-time high in December 2021 on vaccine-vial component demand, de-rated ~50% to ~$233 through 2022, and — after a false 2023 recovery — ground to a $189.58 destocking trough in April 2025 as customers burned off over-ordered inventory. It has since recovered +73% off that low to ~$327.95, sitting in a 52-week range of roughly $209–$335, about 30% below its 2021 peak, with a strong +50.9% twelve-month relative strength. The price narrative is a clean boom → bust → recovery, and the stock is now in the recovery’s re-rating phase.

†The largest single-day move sits at the Feb-2025 FY-guidance reset (the destocking-trough print). Each numbered move is corroborated by a five-year price series cross-referenced to earnings dates/prints, 8-K events, guidance changes, and the news feed (see the Source Appendix). The opportunity/mispricing judgment belongs to Author’s Take above; this block states only what happened and why.

1. Executive Summary

West Pharmaceutical Services is the dominant global maker of injectable drug containment and delivery components — the elastomer stoppers, seals, and plungers that seal vials and prefilled syringes and physically contact the drug — plus self-injection devices and contract device manufacturing. FY2025 revenue was $3,074.1M (+6.3% YoY, a new high) across two segments: Proprietary Products ($2,492.1M, 81.1% of sales, 26.4% segment operating margin, ~91% of segment profit) — the high-value elastomer franchise (Westar, NovaPure, FluroTec, Daikyo Crystal Zenith) — and Contract-Manufactured Products / “West Vantage” ($582.0M, 18.9%, 10.9% margin), a lower-margin device-assembly business. Within Proprietary, high-value products (HVP) are ~60% of total sales and ~all of the margin uplift; biologics are ~40% of sales and rising.

The business is elite; the debate is the price. West’s moat is a textbook Greenwald demand-captivity advantage rooted in regulatory switching costs: its components are specified into customers’ drug master files and validated in stability/compatibility studies, so customers cannot switch suppliers mid-product-life without re-qualification and a regulatory refiling — a multi-year, high-risk undertaking. The result is structural pricing power (price +3.5pts in Q1-2026), gross margins of 35–41% across the cycle, and a return on invested capital that has exceeded its cost of capital every year (26.5% in 2021 down to a 15.4% trough in 2024–25 as a heavy capex build temporarily inflated the capital base). The balance sheet is a net-cash fortress (~$588M net cash, just $110M of goodwill — built organically, not acquired).

The five-year earnings line, however, is a round-trip, not a compound. West over-earned during COVID (vaccine vials drove revenue +31.9% in 2021, gross margin to 41.5%, diluted EPS to $8.67), then suffered a severe customer-destocking correction as customers worked down over-ordered component inventory: EPS fell to a $6.69 trough in 2024 and gross margin to 34.5%. The franchise is now visibly re-accelerating — FY2025 revenue set a new high, and Q1-2026 delivered organic growth +15.3%, HVP components +22.6%, biologics +26%, with management raising the full-year guide to adjusted EPS of $8.40–8.75 (+15–20%). Three secular drivers underwrite the recovery: biologics, Annex 1 (a regulation mandating an upgrade of ~6 billion standard components to higher-margin HVP — <15% complete, a ~+200bps/year multi-year escalator), and GLP-1 injectables (~10% of sales, growing ~50% in 2025).

At ~$327.95 the stock has recovered +51% over twelve months to ~38x the raised FY26 guide / ~45x trailing adjusted EPS / ~27x EV/EBITDA — the richest multiple in its peer cohort, mid-range on West’s own habitually-premium history (~52nd percentile), on a ~2% real free-cash-flow yield. A reverse-DCF implies the price already underwrites a full return to the double-digit-compounding algorithm. The verdicts: the industry is structurally good (a concentrated, regulation-reinforced oligopoly with secular volume growth); the moat is a durable wide moat on the ~60% HVP base (thin on standard components and contract manufacturing); growth is high-quality and re-accelerating; financial quality is high (clean adjusted EPS, fortress balance sheet, real ROIC governor) with the one caveat that the capex build has yet to re-leverage ROIC; capital allocation is intelligent (counter-cyclical buybacks, organic reinvestment). The single tension is valuation: a wonderful franchise at a full fare, with the re-acceleration already in the price and no cushion if it wobbles.

2. Business Overview

2.1 What West makes and sells

Founded in 1923 and headquartered in Exton, Pennsylvania, West makes the primary containment and delivery components for injectable drugs — the parts that touch, seal, and deliver the medicine. The FY2025 10-K reports two segments:

Proprietary Products — $2,492.1M (81.1% of sales), 26.4% segment operating margin, ~91% of segment profit. This is the franchise. It comprises elastomer stoppers and seals for drug vials, plungers and tip-caps for prefilled syringes and cartridges, and self-injection devices. The economically critical distinction is high-value products (HVP) — components that are washed, coated (e.g., FluroTec film), sterilized, and ready-to-use, sold under the Westar (ready-to-sterilize), NovaPure (the premium, fully characterized tier), and Daikyo Crystal Zenith (polymer, glass-alternative) brands — versus standard packaging. HVP commands materially higher prices and margins; West discloses HVP at ~60% of total sales and ~all of the margin uplift. West also holds exclusive IP and a long-standing relationship with Daikyo Seiko of Japan (FluroTec, Crystal Zenith), a genuine technical differentiator.

Contract-Manufactured Products (“West Vantage”) — $582.0M (18.9%), 10.9% margin. Project-based contract manufacturing of devices and assemblies (auto-injectors, inhalation, diagnostics) using customer-owned tooling. Lower margin, less sticky, not the moat — but a funnel that pulls West’s proprietary components into integrated devices.

2.2 How it makes money; recurring quality

West’s revenue is a consumables toll: a component is consumed with every vial filled and every syringe assembled, so revenue scales with the unit volume of injectable doses produced — a razor-and-blade dynamic where the installed base of approved drugs is the razor and the per-dose component is the blade. This is high-quality, recurring-in-character revenue: once a drug is approved with a West component specified, West supplies that component for the commercial life of the drug. End markets are biologics ~40%, pharma ~24%, generics ~17% of sales, with the balance in contract manufacturing and other. The business is ~57% ex-US (a global manufacturing and customer footprint), with manufacturing concentrated in the US, Ireland, Germany, and elsewhere.

2.3 Customer concentration — the structural caveat

The one genuine fragility in an otherwise pristine model is concentration: the top-10 customers are 47.6% of sales, and a single customer is 15.8% ($485.9M), rising fast from 10.9%→12.3%→15.8% over three years — a trajectory consistent with a large GLP-1 manufacturer scaling. This is the mirror image of the GLP-1 tailwind: the same force driving the growth is concentrating the revenue base, so a disruption to that one relationship or molecule class would hit growth and mix at once (see Risk Analysis).

Verdict — Business Overview. A high-quality, recurring-in-character consumables franchise selling the indispensable components of injectable drugs, anchored by a high-margin HVP proprietary segment (~81% of sales, ~91% of profit) and supported by a lower-quality contract-manufacturing leg. Revenue quality is high — installed-base, per-dose, regulation-locked — with the single caveat of rising customer concentration. Not a subscription model, but as close to a recurring industrial toll as a components manufacturer gets.

3. Industry Dynamics

3.1 Structure of the injectable-components industry

The market for injectable drug containment and delivery is a concentrated oligopoly with regulation-reinforced barriers. In elastomer closures — the core — West is the clear #1, with Datwyler (Swiss) the #2 and Aptar Pharma (a division of AptarGroup, ATR) the #3; in glass and syringe systems the players are Stevanato (STVN), Schott Pharma, Gerresheimer, and BD (Becton Dickinson, the prefilled-syringe leader); polymer alternatives include SiO2. The barrier to entry is not capital — it is qualification: a component must be validated by the drug-maker, written into the regulatory filing, and proven in stability studies, so incumbency on an approved drug is nearly absolute, and winning a new molecule requires a multi-year technical and regulatory bake-off. This is why the industry’s structure has been stable for decades and why returns persist.

3.2 The secular tailwinds — and their quality

Three forces drive structural volume growth, and their quality differs:

• Biologics (~40% of West’s sales, the highest-quality driver): large-molecule drugs are overwhelmingly injectable, sensitive to container interactions, and therefore disproportionately use West’s premium NovaPure/HVP components. The biologics pipeline is deep and growing; this is durable, mix-accretive, multi-decade demand.
• Annex 1 (the underappreciated regulatory escalator): the EU’s revised Annex 1 sterile-manufacturing standard effectively mandates higher-quality, ready-to-use components — mechanically converting West’s lower-margin standard packaging (20–30% gross margin) into HVP (60%+). Management frames this as ~6 billion components to upgrade, <15% complete, 700+ projects initiated, a ~+200bps/year tailwind for years. It is regulation-driven (not demand-elastic) and margin-accretive — arguably the highest-quality driver in the story.
• GLP-1 (~10% of sales, the loudest but not the best driver): weight-loss/diabetes injectables drove ~50% component growth in 2025. The content is real (a vial stopper, an auto-injector plunger and components, a pen cartridge seal). But it is the lower-quality driver: concentrated in one customer, more commoditizable at the elastomer level (Datwyler/Aptar also supply), and exposed to oral-GLP-1 substitution risk over 3–5 years. Management’s base case conservatively embeds >30% oral penetration by 2030 and argues orals expand the market (“8 of 10 oral patients are new to market”); the risk is real but bounded.

3.3 Marathon capital-cycle read

COVID was a textbook capital-cycle whipsaw: extraordinary vaccine-vial demand pulled forward orders and pulled in capacity, the demand cliff and customer destocking then ate the over-build (West’s own ~$1.3B 2022–25 capacity investment is the asset-growth-anomaly footprint), and the cycle is now normalizing with demand again outrunning supply in 2025–26. Crucially, supply discipline holds at the industry level — the qualification barrier blocks destabilizing new entrants, so unlike a commodity, the over-build does not invite a price war; it simply depresses utilization until volume catches up (which it now is). The capital cycle here is favorable on the other side of the destock — but it is a reminder that West’s demand is more cyclical (via customer inventory) than the “consumables toll” framing alone implies.

Verdict — Structurally GOOD. A concentrated, qualification-gated, regulation-reinforced oligopoly with durable secular volume growth (biologics, Annex 1, prefilled syringes, GLP-1). It is more cyclical than it looks — customer destocking can and did cut revenue and crush margins — but the structure is among the most attractive in healthcare supply, and the post-destock capital cycle is favorable.

4. Competitive Position

4.1 The moat — named, tied to financials, and bounded

The drug-master-file lock-in is a genuine wide moat, and it sits exactly where the margin and growth are: the HVP proprietary base. Management describes it directly: once a customer is “specced into our products and references our drug master file, there is a dependency… highly unlikely that customers will change partners” — and even qualifying a second West site for an approved product takes 6–12 months. The moat is financially proven by ROIC above WACC in every year of the cycle (including the destock trough) and by live pricing power. It is bounded, however: it protects the ~60% HVP base, not the ~20% standard packaging (commodity, though Annex 1 is upgrading it) or the ~19% contract-manufacturing leg (no moat). The honest read is a wide moat on the majority of the business, thin-to-absent on the rest — and, critically, the moat is widening as Annex 1 converts standard into HVP.

4.2 Head-to-head and the new-molecule contest

On approved drugs, West’s incumbency is near-absolute (switching is uneconomic). The genuine competition is for new molecules, where Datwyler and Aptar are credible and bake-offs are real — West’s edge there is its install-base relationships, scale, NovaPure characterization data, and the Daikyo IP, not invincibility. Against the glass/syringe players (Stevanato, Schott, Gerresheimer, BD), West competes in the integrated-device and Crystal-Zenith-polymer arenas rather than head-on in glass. A useful cross-read: BD is the prefilled-syringe leader riding the same GLP-1/biologics wave, but its returns are diluted by overpaid M&A (ROIC ~6%) — the contrast underscores that West’s ~15–26% ROIC is a function of an organically-built franchise, not financial engineering.

Verdict — A durable WIDE moat on the majority of the business, and widening. Regulatory drug-master-file captivity, reinforced by scale and exclusive IP, is one of the better moats in healthcare supply — financially proven by persistent above-WACC returns and pricing power. It is bounded (standard packaging and contract manufacturing are not moated), but Annex 1 is mechanically expanding the high-moat share of revenue. Durable advantage, correctly the crown jewel.

5. Growth History and Forward Opportunities

5.1 History — a COVID round-trip, not a compound

The five-year line is the bear’s exhibit: diluted EPS went $8.67 (2021) → $6.79 (2025) — flat-to-down across four years. But the cause is specific and arguably non-structural: a COVID over-earn (vaccine vials drove the 2021 peak) followed by a customer destocking correction (2022–24) as drug-makers worked down over-ordered component inventory — not a secular demand failure. Underlying drug demand never fell; customer inventory did. FY2025’s +6.3% to a new revenue high marked the inflection.

5.2 The re-acceleration — real and broad-based

The recovery is not a one-line comp bounce; it is broad and confirmed:

• Q1-2026: organic sales +15.3%, HVP components +22.6%, biologics +26%, price +3.5pts, operating margin +350bps, adjusted EPS $2.13 (+47%) — well above guidance.
• Guide raised at Q1 from the initial $7.85–8.20 (set in February) to $8.40–8.75 adjusted EPS (+15–20%) and organic growth back to the “long-term construct of 7–9%.”

5.3 Forward drivers, ranked (size × durability × quality)

1. Biologics + Annex 1 (the highest-quality core): together ~4–5 of every ~7 points of FY2026 growth. Biologics is durable, mix-accretive, multi-decade; Annex 1 is a regulation-mandated, margin-accretive, multi-year escalator (<15% done). This is the part of the story I would pay for.
2. HVP mix-shift: the structural margin lever — converting standard to NovaPure/Westar across the portfolio.
3. GLP-1 (~10% of sales, ~1 of 7 growth points): real and fast-growing but the lower-quality driver — concentrated, more commoditizable, oral-substitution-exposed.
4. Prefilled syringes / self-injection devices + Contract Mfg: device content per drug rising; lower margin but pulls components through.
5. Geographic / capacity: the new HVP capacity (the ~$1.3B build) now has demand to fill.

Verdict — HIGH-QUALITY growth, re-accelerating, with the quality concentrated in the durable drivers (biologics + Annex 1) rather than the loud one (GLP-1). The four-year flat-EPS history is a COVID-distortion artifact, not a franchise indictment; the 2025–26 inflection is broad-based (price + biologics + Annex 1, not a single product), demand is outrunning supply, and management raised guidance. The legitimate caution is that the magnitude and durability of the re-acceleration — and the margin recovery underpinning it — are now the base case in the valuation (see Valuation), so the growth must simply deliver, with little room for disappointment.

6. Financial Quality

6.1 The margin arc — the central question

The whole financial debate is the gross margin: 41.5% (2021 COVID peak) → 34.5% (2024 destock trough) → 35.9% (2025); operating margin 26.8% → 20.4% → 20.7%. Is the through-cycle margin closer to the 40% peak or the 35% trough? The evidence says neither extreme: 2021 was a genuine over-earn (peak vaccine HVP mix on fully-absorbed plants), and 2024 was a genuine under-earn (volume deleverage on the new capacity built ahead of demand, plus a one-time ~$47M customer incentive that did not repeat). The economically relevant Proprietary Products segment margin — stripping the dilutive ~16.5%-margin contract-manufacturing leg — ran 43.1% (2023) → 38.6% (2024 trough) → 40.5% (2025), already most of the way back. Management names the recovery drivers as structural: HVP mix, plant absorption (filling the capacity), and price. Q1-2026 confirms the re-expansion (total GM 35.1%, +190bps; op margin 21.4%, +350bps; guidance for further H2 expansion). The defensible normalized level is consolidated ~37–39% gross / ~22–24% operating — above the trough, below the COVID peak. This is the number the valuation should anchor to.

6.2 Quality of earnings — clean

West’s earnings quality is high and clean:

• Adjusted vs GAAP is legitimate and small: FY2025 GAAP diluted EPS $6.79 → adjusted $7.29 (+8%); the entire $0.50 bridge is operational (restructuring $0.31, SmartDose-sale $0.09, a cost-method investment mark $0.06, amortization $0.03). Critically, there is no stock-comp tax-windfall add-back flattering the adjusted number (a common low-quality trick) — the equity-comp excess tax benefit runs through the GAAP tax line and is fading (effective rate rose 14.3%→20.2% over five years, a mild GAAP headwind, not an adjusted-EPS inflator).
• Cash backs the earnings: operating cash flow exceeds net income (OCF/NI ~1.3–1.5x).
• Net interest is now income (net cash).

6.3 The capex caveat and ROIC

The one genuine quality knock is that the heavy capacity build has temporarily depressed both FCF and ROIC. ROIC fell 26.5% (2021) → 22.0 → 18.6 → 15.4 → 15.4% (2025) as ~$1.3B of 2022–25 capex grew the invested-capital base faster than NOPAT recovered — still elite versus an ~8% WACC, but a real decline. And because the screens (ROIC.ai, yfinance) mislabel operating cash flow as “free cash flow,” the headline overstates true FCF by ~35–40%: real FCF (OCF − capex) was ~$436M (2022) / $408M (2023) / $274M (2024) / $469M (2025) — a ~2% real FCF yield on the current ~$23B market cap. The good news: capex is moderating ($379M → $286M → a $250–275M FY2026 guide, ~8% of sales), so the build is largely done and FCF should re-expand as the new capacity fills. The open question is whether GLP-1/HVP volume re-leverages ROIC back toward 20%+ — Q1-2026 (HVP components +22.6%) is early, encouraging validation, not yet proof.

6.4 Balance sheet — fortress, organic

Pristine. Cash $791.3M against ~$321M of total debt (mostly leases) = net cash ~$588M; goodwill just $110M and intangibles $118M (an organically-built franchise, not an acquisition stack); positive tangible equity (TCE ratio ~74%); current ratio 3.0. This is the balance sheet of a business that compounds by building plants and reinvesting, not by levering up — and it is the single best contrast with the levered-roll-up names in the sector.

Verdict — Financial Quality: HIGH. Clean, defensible adjusted earnings (no tax-windfall games), cash-backed net income, a net-cash fortress, and a structurally high (if temporarily capex-depressed) ROIC. The two honest caveats are (1) the normalized margin sits ~37–39% GM, not the 40%+ bulls anchor to or the 36% bears fear, and (2) ROIC must re-leverage off the 15% trough to justify the premium — an unproven, in-progress bet. Anchor valuation to ~$7.29-and-growing adjusted EPS, ~$470–550M normalizing FCF, and the ~37–39% margin — not the COVID peak.

7. Capital Allocation

7.1 The record — disciplined, organic, counter-cyclical

West’s capital allocation is a genuine strength and a differentiator versus the sector:

• Organic reinvestment over M&A: West barely acquires (goodwill just $110M). It compounds by building qualified capacity — the right model for a qualification-moat business, and the source of its high organic ROIC (contrast BD’s overpaid-M&A ~6% ROIC).
• Counter-cyclical buybacks: repurchases were $451M (2023) and $567M (2024) — concentrated at the destocking-trough lows (~$200–350) — then throttled to $137M (2025) as the stock recovered, then $298M in Q1-2026 (~$248/share) on a dip. Buying heavily when the stock was cheapest is exactly the discipline one wants; a new $1B authorization is in place. Shares fell ~5% over five years (76.3M → 72.0M).
• Token-but-growing dividend: ~0.26% yield, ~12% payout — appropriate for a reinvestment-rich compounder.
• Small portfolio pruning: the SmartDose 3.5mL wearable-injector platform is being divested to AbbVie (~$120–130M, closing mid-2026) — sensible focus.

7.2 Incentives — a rare real ROIC governor

The compensation plan is, unusually for the names I cover, well-designed: performance shares (50% of long-term incentive) vest on 3-year sales CAGR and ROIC, equally weighted — an actual return-on-capital governor, not just an EPS/revenue growth target. And it has teeth: the 2023–25 PSUs paid only 41% as the destocking cycle missed targets, so pay genuinely flexed down with performance. This is a meaningful positive versus the “no-ROIC-metric, pays-for-size” compensation designs that plague much of the market.

7.3 Insiders and the CEO transition

• Insiders: across all 178 Form 4s in the five-year corpus there were zero open-market purchases (code P) — activity is entirely grants, vesting, and routine option-exercise-and-sell (e.g., CAO Winters and CHRO Favorite exercised-and-sold in April 2026). No conviction-buy signal — a mild negative, though typical for an expensive compounder.
• CEO transition (orderly, well-credentialed): long-tenured Chair/CEO Eric Green (since 2015) is retiring; Michel Lagarde, 52, becomes President & CEO effective August 31, 2026. Lagarde is an external hire — EVP & COO of Thermo Fisher Scientific (joined TMO via the Patheon CDMO acquisition, where he was President & COO; earlier JLL Partners healthcare PE and Philips finance; Vertex board audit/finance chair). On his start the Chair and CEO roles split — Lead Independent Director Robert Friel becomes Chair (a governance upgrade). The read: a capital-disciplined operator/integrator profile (not a scientist), signaling continuity on the operational-excellence/margin agenda and plausibly greater openness to M&A — paired with a new CFO (McMahon) building a formal capital-allocation policy. Best-practice succession; the real risk is simply execution at the GLP-1/Annex-1 inflection.

Verdict — Capital Allocation: INTELLIGENT (a thesis strength). Organic reinvestment in a qualification-moat business, counter-cyclical buybacks executed at the lows, a fortress net-cash balance sheet, a rare genuine ROIC compensation governor that actually flexed pay down, and an orderly, well-credentialed CEO succession with a governance upgrade. The only blemishes are the absence of insider open-market buying and the unproven question of whether the heavy capex re-leverages ROIC. This is how a high-quality compounder should be run.

8. Changes and Headwinds — Last Two Years

The destocking cycle and recovery (the central change): the 2023–24 customer-inventory destock cut revenue and crushed margins (gross margin 41.5%→34.5%, EPS to a $6.69 trough), bottoming with the February-2025 guidance reset; the 2025–26 re-acceleration (FY2025 +6.3% to a new high; Q1-2026 organic +15.3%, guide raised to +15–20% EPS) is the reversal. This dominates the two-year financial narrative.

Leadership and governance: the CEO transition (Green → Lagarde, effective 8/31/26), the Chair/CEO split (Friel → Chair), and a new CFO (McMahon) building a formal capital-allocation policy — a meaningful refresh of the top team at an inflection.

Portfolio: the SmartDose 3.5mL divestiture to AbbVie (~mid-2026); the new $1B buyback authorization.

Capacity: the ~$1.3B 2022–25 capex build (HVP/GLP-1 capacity, Ireland/Arizona) is largely complete and now moderating (FY2026 capex guide $250–275M), shifting the company from a build phase to a fill-and-harvest phase.

Headwinds/overhangs: (1) valuation — ~38x forward, the richest in the cohort, ~2% real FCF yield (the dominant risk); (2) customer concentration — one customer 15.8% and rising; (3) GLP-1 oral-substitution risk over 3–5 years; (4) a May-2026 cyberattack — an intrusion detected May 4 / confirmed material May 7 (data exfiltrated, systems locked), fully operational by May 20 with no material financial impact disclosed, but a residual data-exfiltration tail; (5) execution risk under a new CEO at the GLP-1/Annex-1 inflection; (6) FX (~57% ex-US).

Verdict — On balance, the changes STRENGTHEN the operating thesis (destock over, re-acceleration confirmed, governance upgraded, capex peaking) while raising the bar on valuation and adding a new-CEO execution variable. The franchise is in materially better operating shape than two years ago; the question the changes do not answer is whether the recovery justifies a multiple that already assumes it.

9. Risk Analysis

Likelihood and Impact each Low/Med/High over a ~12–24 month horizon; “Impact” = effect on intrinsic value / the thesis.

Risk-matrix summary. The dominant quadrant is #1 (valuation), and it is correlated with #2–#5: because the price carries no cushion, any growth or margin disappointment (a customer stumble, an oral-GLP-1 acceleration, a margin stall, an ROIC that won’t re-leverage) compresses a 38x multiple toward the peers’ 20x — a fast, large de-rate. The franchise risks (destock recurrence, new-molecule competition) are real but bounded by the moat. Catastrophic loss is not a realistic scenario — this is a net-cash, wide-moat, cash-generative market leader; the realistic downside is a valuation de-rate to the destock-trough zone, not capital impairment. The aggregate risk is priced-for-perfection, not solvency.

10. Valuation Discussion — Embedded Expectations

No price target, no recommendation. Embedded-expectations and scenario framing only.

10.1 Live recompute and the multiples

At $327.95 (~72.0M shares), market cap is ~$23.0B; with net cash ~$588M, EV ~$22.4B. (ROIC’s screen EV uses a stale ~$251 price — discard it.) The multiples:

10.2 Own-history and the comp set — richest in the cohort

On its own history, West’s ~27x EV/EBITDA and ~44x P/E are mid-range ( composite ~52nd percentile; P/E ~44th) — because West habitually trades at a premium (a 10-year average P/E ~45x, EV/EBITDA historically 19–39x). So this is not an extreme-percentile name like a frothy industrial; it is a habitually-expensive elite franchise at its usual premium. Against the cohort, however, West is the most expensive name in the group:

West trades at ~27x EV/EBITDA versus the best-quality tools peers at 20–22x and at roughly 2x the EV/EBITDA of its direct pharma-packaging competitors (Stevanato/Aptar at ~12x). The premium is the market paying for the widest moat in the group (drug-master-file lock-in, ROIC>WACC every year), the biologics/Annex-1/GLP-1 secular story, and the cleanest balance sheet. It is justified only if the re-acceleration is structural; it is pricing perfection if 2025–26 proves to be a destock-bounce that fades.

10.3 Embedded expectations — the full algorithm, no cushion

A two-stage reverse-DCF (WACC ~8.5%, terminal 3%) shows that to justify EV ~$22.4B, the price requires a ~14% FCF compound sustained ~10 years — even off a normalized ~$550M FCF base (post-capex-moderation). At 8% / 10% / 12% FCF CAGR the model supports only ~$15B / $18B / $21B of EV. So the market is underwriting a full return to the double-digit-compounder algorithm: ~7–9% organic growth + gross-margin recovery toward 38–40% + ROIC re-leveraging from the 15% trough back toward 20%+. With a ~2% real FCF yield and a multiple already mid-its-range, there is essentially no valuation cushion — all forward return must come from earnings compounding; none from re-rating or yield. The asymmetry: the upside requires the algorithm to deliver as expected (already priced), while the downside (a customer/margin/GLP-1 wobble) compresses the multiple toward the peer 20–22x.

10.4 Scenarios (per-share zones; NOT price targets)

The base case roughly re-derives today’s price — you earn roughly the compounding if the algorithm delivers in line, with little margin of safety. The bear (~$190–250) is a re-test of the destock-trough zone the stock printed only a year ago, requiring only a margin stall or a GLP-1/customer disappointment plus compression toward the peer multiple. The bull (~$430–490+) revisits the 2021 ATH and requires the full algorithm plus a sustained premium. The reward/risk at ~$328 is roughly symmetric-to-slightly-negative: the bear needs only one thing to go wrong against a cushionless multiple, while the bull needs the whole algorithm to compound and the premium to persist.

Verdict. West trades at ~38x forward / ~27x EV/EBITDA / ~2% real FCF yield — the richest multiple in its peer cohort and mid-range on its own habitually-premium history. The price embeds a full return to the double-digit-compounding algorithm (7–9% organic, ~40% gross margin, ROIC re-leverage) with no valuation cushion. This is a wonderful business correctly recognized as such — the question is not quality but whether to pre-fund the re-acceleration at a price that already assumes it.

11. Variant Perception

Consensus has converged on a constructive view: West is a wide-moat, high-quality compounder whose COVID-destock is over, whose secular drivers (biologics, Annex 1, GLP-1) are re-accelerating growth back to the long-term algorithm, and whose premium multiple is therefore deserved. Barclays’ June-2026 upgrade to Overweight (PT $400) and the +51% twelve-month rally embody this. It is a quality re-rating on the recovery, not a value or contrarian thesis.

The strongest bull case: a genuinely wide regulatory moat (drug-master-file lock-in, ROIC>WACC every year, pricing power), riding three real secular tailwinds with the highest-quality ones (biologics + Annex 1) carrying most of the growth; a broad-based, confirmed re-acceleration (Q1-26 organic +15.3%, HVP +22.6%, guide raised); a margin recovery already visible (Proprietary segment back to 40.5%); a fortress net-cash, organically-built balance sheet; intelligent, counter-cyclical capital allocation with a real ROIC governor; and capex peaking, so FCF and ROIC should re-expand. “The indispensable, regulation-locked toll on every injectable, re-accelerating off a destock trough with multi-year secular tailwinds — a quality compounder worth a premium.”

The strongest bear case: a wonderful business at a cushionless price (~38x forward, ~27x EV/EBITDA, ~2% real FCF yield, the richest in its cohort) that already embeds a full return to the algorithm; four years of flat EPS that the bulls wave away as a COVID artifact but which also exposed real cyclicality (customer destocking cut revenue and crushed margins); a through-cycle margin that may settle nearer 36% than 40%; a ROIC that fell to 15% and is unproven to re-leverage; rising single-customer concentration (15.8%) colliding with oral-GLP-1 substitution risk; zero insider buying; and a brand-new CEO at the inflection. “A great franchise priced for perfection at the top of a recovery, with no cushion if the margin or the marquee customer disappoints.”

The variant view (where I differ from the tape): I think consensus is right about the business and complacent about the price. The market has correctly identified one of the better moats in healthcare and a genuine re-acceleration — and then paid for all of it, pricing the bull algorithm as the base case while the stock has already rallied 51%. The factor read corroborates a fully-recovered, not-cheap setup: beta 0.705, +50.9% twelve-month relative strength (strong positive momentum, not a falling knife), but 3- and 5-year returns flat-to-negative (the COVID round-trip is fully unwound) — so this is now a pure earnings-compounding bet, not a re-rate or mean-reversion bet, with no valuation tailwind to lean on. Consensus is most likely offsides in underweighting the cushionless downside: at a 38x multiple correlated with a single 15.8% customer and an unproven margin/ROIC recovery, the probability-weighted outcome is less attractive than the deserved-premium narrative implies, because the bear requires only one disappointment while the bull requires the entire algorithm plus a persistent premium.

The single most important monitorable: the gross-margin trajectory and ROIC re-leverage over the next 2–4 quarters — a clean march back toward 38–40% consolidated gross margin (and ROIC off the 15% trough) would confirm the structural-recovery thesis and validate the premium; a stall near 36% would confirm a permanent reset and a cushionless multiple. Secondary monitorables: the top-customer concentration trend and any GLP-1 oral-substitution data points, and the new CEO’s first strategic/capital-allocation signals.

12. Fact vs. Interpretation Table

13. Open Questions

1. The normalized margin. Does gross margin recover toward 38–40% (HVP mix + Annex 1 + absorption) or settle nearer 36%? This is the single biggest valuation swing factor — watch the next 2–4 quarters.
2. ROIC re-leverage. Does the ~$1.3B capacity build fill and push ROIC off the 15% trough back toward 20%+, or do returns stay structurally lower than the pre-COVID franchise?
3. The 15.8% customer. Who is it, how concentrated does it get, and how exposed is it to oral-GLP-1 substitution? A disclosed deceleration here would be a major tell.
4. GLP-1 oral substitution. Does the >30%-by-2030 oral-penetration base case prove conservative or optimistic, and is the “orals expand the market” framing borne out?
5. The new CEO’s strategy. Does Lagarde (ex-TMO/Patheon) keep West an organic compounder, or does the operator/integrator profile (plus a new CFO building a capital-allocation policy) signal a shift toward M&A?
6. Capex normalization. Does capex truly settle at ~8% of sales (the $250–275M guide), restoring the FCF the premium needs?

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true

1. The re-acceleration is structural, not a destock-bounce, and compounds EPS double-digit. Falsifies the bull if: organic growth decelerates back to low-single-digit within a few quarters, or the guide is cut as the easy comps lap.
2. Gross margin marches back toward 38–40% and ROIC re-leverages off 15%. Falsifies the bull if: consolidated gross margin stalls near 36% for several quarters, or ROIC fails to climb as capex moderates.
3. The premium multiple is sustained by the moat + secular drivers. Falsifies the bull if: the multiple compresses toward the peer 20–22x EV/EBITDA on any growth/margin wobble — likely given no cushion.

Bear case — what must be true

1. The price embeds a full algorithm with no cushion, so any disappointment de-rates hard toward the destock-trough zone. Falsifies the bear if: West compounds adjusted EPS in the mid-teens for multiple years while holding the premium multiple, making today’s price look cheap in hindsight.
2. The recovery exposed real cyclicality and a margin that resets nearer 36%. Falsifies the bear if: gross margin sustainably exceeds 38% and the business proves the destock was a one-off, not a feature.
3. Customer concentration + oral-GLP-1 substitution is an underpriced tail. Falsifies the bear if: the top customer diversifies/stabilizes and injectable GLP-1 volumes keep growing despite oral launches (orals genuinely market-expanding).

15. Source Appendix

The full source list is maintained in the separate Source Appendix (Appendix B of the combined report). Primary sources include: West FY2021–FY2025 10-Ks (EDGAR, CIK 0000105770), the Q1-FY2026 10-Q, the FY2025 and Q1-FY2026 earnings 8-Ks (EX-99.1 press releases, including the FY2026 guide raise to adjusted EPS $8.40–8.75), the CEO-transition 8-K (Item 5.02, 6/1/26), the DEF 14A proxy (the ROIC-based PSU compensation design), Form 4 insider filings, and EDGAR XBRL companyfacts; the ROIC.ai financial database (statements, ratios, EV, multiples) and earnings-call transcripts (Q3-FY25, Q4-FY25, Q1-FY26); the FactorsToday factor model (loadings, leaderboard, factor-similar peers); price history and news feeds (the Barclays upgrade, the CEO transition, the cyberattack disclosure); public filings and market data for the life-sciences-tools peer set (RGEN, AVTR, WAT, BDX, DHR, TMO) for cohort framing and the destocking analog; and public market data. Each is cited with access date 2026-06-21. Management commentary is treated throughout as hypothesis and validated against filings, financials, and external evidence.

The analysis in this article carries no investment recommendation and no price target; the Author’s Take block is a separately-labeled subjective view. This is general information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Answers grounded in the underlying research; Fact / Interpretation / Assumption labels applied where it matters. Greenwald (Competition Demystified) and Marathon (Capital Returns) frameworks applied where they add insight. Report date: 2026-06-21.

General

What thoughtful questions have other investors asked about this company? The debate clusters around five themes: (1) Is the through-cycle margin closer to the 40% COVID peak or the 35% destock trough? — the single biggest valuation swing factor. (2) Is the 2025–26 re-acceleration structural or a destock-bounce that fades? — Q1-26 organic +15.3% and a raised guide say structural; bears note four years of flat EPS. (3) How real and durable is the GLP-1 tailwind, and how dangerous is the rising 15.8% single-customer concentration plus oral-substitution risk? (4) Will ROIC re-leverage off the 15% trough now that the ~$1.3B capex build is moderating, or has the franchise’s return profile structurally reset lower? (5) Is a ~38x forward / ~27x EV-EBITDA multiple — the richest in the cohort — justified by the moat and secular drivers, or pricing perfection? On the recent calls the sell-side focused on margin cadence (H2 expansion), Annex-1 conversion pace, GLP-1 sizing/oral risk, capex normalization, and the CEO transition — precisely the load-bearing assumptions in our variant view.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation) Recovering from a cyclical low toward mid-cycle. FY2024 was a genuine destock-trough under-earn (EPS $6.69, gross margin 34.5%); FY2025 inflected (revenue new high) and FY2026 is re-accelerating (guide +15–20% EPS). Earnings are below the 2021 COVID peak but above the 2024 trough and rising — neither a clean high nor a clean low, but on the upswing.

Driven by the external environment or internal actions? (Interpretation) Both. External: customer inventory cycles (the destock), biologics/GLP-1 secular demand, and Annex-1 regulation. Internal: the HVP mix-shift strategy, capacity build, pricing, and operational-excellence margin programs. The volume swings are largely external (customer ordering); the margin recovery is substantially internal (mix + absorption + price).

How stable are revenues? (Fact) More cyclical than the “consumables toll” framing implies. Revenue swung +31.9% (2021), then flat/down through the destock (2022–24), then +6.3% (2025). The underlying drug demand is stable; the customer inventory layer adds real cyclicality. Beta 0.705 (defensive-ish).

Outlook for products/services? (Fact, mgmt = hypothesis) Management guides FY2026 organic 7–9% and adjusted EPS $8.40–8.75 (+15–20%), with multi-year secular drivers (biologics, Annex 1, GLP-1, prefilled syringes). The outlook is genuinely improving; the question is durability and the margin path.

How big will this market be — growing, shrinking, domestic or international? (Fact) The injectable-components market grows mid-single-digit-plus structurally (biologics shift, injectable unit growth, regulatory upgrades), with GLP-1 an additional kicker. West is ~57% ex-US — a global franchise. Growing.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? (Interpretation) Stable. A concentrated, qualification-gated oligopoly (West #1, Datwyler #2, Aptar #3 in elastomers). New entrants are blocked by the qualification/regulatory barrier; the real contest is for new molecules, where competition exists but incumbency on approved drugs is near-absolute.

How profitable is the business (ROIC, ROE)? (Fact, computed) ROIC 26.5% (2021) → 15.4% (2025 trough) — still well above an ~8% WACC every year; ROE 30.5% → ~16%. The decline is a temporary capex-base effect, not a moat erosion. Proprietary segment operating margin 26.4%; consolidated ~20.7% (recovering).

How profitable is the industry — how many competitors, what barriers to entry? (Fact/Interpretation) A ~3-player elastomer oligopoly with very high qualification/regulatory barriers — among the more profitable niches in healthcare supply. West’s HVP gross margins reach 40%+; standard packaging and contract manufacturing are lower.

Can the business be easily understood? (Interpretation) Yes at the model level (sell the components consumed per injectable dose), though the margin normalization (COVID over-earn vs destock under-earn) and the HVP-mix accounting require care.

Can it be undermined by foreign low-cost labor? (Interpretation) Largely no. The moat is regulatory qualification + scale + IP, not labor cost. Components are validated into specific approved manufacturing sites; a low-cost entrant cannot simply undercut on price without years of qualification. Standard packaging is more contestable.

Do brands matter? (Fact) Yes — at the B2B/technical level. NovaPure/Westar/FluroTec/Crystal Zenith are trusted, characterized, regulatory-referenced brands; the “brand” is really a qualification-and-data asset that customers spec into filings. Consumer brand is irrelevant; technical brand/qualification is decisive.

What is the nature of competition? (Interpretation) Qualification + technical performance + supply reliability + data/regulatory support on new molecules; near-zero switching on approved drugs.

Customers’ switching costs? (Fact) Very high — the core of the moat. Switching a component on an approved drug requires re-qualification + a regulatory refiling = years + risk, so customers don’t. Even qualifying a second West site takes 6–12 months. This is the most durable Greenwald advantage type (demand captivity).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? (Interpretation) Yes — the portfolio of drug-master-file qualifications (thousands of approved-drug component specs) is an enormous unbooked intangible; it is the moat and it carries essentially no balance-sheet value. The Daikyo IP relationship is similarly understated.

Off-balance-sheet liabilities? (Fact/Open Question) Minimal — modest operating leases and pension. The principal contingent item is the May-2026 cybersecurity incident (data exfiltrated; no material financial impact disclosed) — a residual data/litigation tail.

How conservative is the accounting? (Interpretation) Conservative/clean. Adjusted EPS adds back only legitimate operational items (restructuring, divestiture, amortization) with no stock-comp tax-windfall inflation; OCF exceeds NI; revenue recognition is straightforward (point-of-shipment components). High quality.

How CapEx-hungry is the business? (Fact) Capital-intensive and recently elevated — capex ran ~10–13% of sales (~$286–379M/yr) building HVP/GLP-1 capacity, now moderating to a ~$250–275M (~8% of sales) FY2026 guide. This is a real call on cash (it depresses true FCF to ~$469M, a ~2% yield) but the build is largely complete and should harvest as capacity fills.

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy? (Fact) Real FCF (OCF − capex) ~$469M FY2025 (after a ~$274M capex-trough year). Uses: organic capacity reinvestment (the priority) + counter-cyclical buybacks + a token-but-growing dividend. Philosophy: build qualified capacity, return excess opportunistically (heavy buybacks at the lows), keep a fortress net-cash balance sheet. Intelligent and consistent.

Significant acquisitions recently? (Fact) No — West is an organic builder (goodwill just $110M). Recent portfolio action is a divestiture (SmartDose 3.5mL to AbbVie, ~mid-2026). The new CEO/CFO may open the door to more M&A — a watch item, not a fact.

Buying back shares? (Fact) Yes, and well-timed — $451M (2023) and $567M (2024) at the destock-trough lows, throttled to $137M (2025) on recovery, $298M in Q1-26 on a dip; a new $1B authorization. Shares −5% over five years. Genuinely counter-cyclical.

Issuing large amounts of new shares to insiders? (Fact) No — modest equity comp; net share count falling via buybacks.

Compensation policy of directors/management? (Fact) A rare genuine ROIC governor — PSUs (50% of LTI) on 3-year sales CAGR + ROIC, equally weighted; 2023–25 PSUs paid only 41% (pay flexed down through the destock). A meaningful positive versus the no-ROIC-metric designs common elsewhere.

Motivations of management? (Interpretation) A capable, returns-aware team transitioning leadership: long-tenured Eric Green retiring; Michel Lagarde (ex-Thermo Fisher COO, ex-Patheon) incoming as CEO (8/31/26) with the Chair/CEO roles splitting (governance upgrade). The incoming profile is an operator/integrator with capital discipline — continuity on margins, possible openness to M&A. Aligned by an ROIC-linked plan; the absence of insider open-market buying is a mild caveat.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? (Fact) No — a US C-corporation (Pennsylvania), NYSE-listed common, single class, standard Form 1099.

Dividend policy? (Fact) A token but consistently growing dividend (~0.26% yield, ~12% payout) — a long record of small annual increases; capital return is buyback-led, appropriately.

How profitable is the business? (Fact) Gross margin ~36% recovering (Proprietary segment ~40%), operating margin ~21% recovering toward mid-20s, ROIC 15.4% (trough) vs ~8% WACC, net margin ~16%. Elite returns, temporarily capex-depressed.

Is net income diverging from cash from operations? (Fact) No adverse divergence — OCF exceeds NI (~1.3–1.5x); the only nuance is that capex (not an NI/OCF gap) is what reduces true FCF.

Risks & Downside

What factors would cause the stock to decline? (Interpretation) In order of likelihood × impact: (1) multiple compression from the cushionless ~38x level on any disappointment; (2) a margin recovery that stalls near 36%; (3) a top-customer (15.8%) shock or faster oral-GLP-1 substitution; (4) ROIC failing to re-leverage; (5) a destock recurrence. These correlate — a growth/margin wobble de-rates the premium toward the peer 20–22x.

Risk of a catastrophic loss? (Interpretation) Low. A net-cash, wide-moat, cash-generative market leader; the realistic downside is a valuation de-rate to the ~$190–250 destock-trough zone, not capital impairment.

Chance of a total loss? (Interpretation) Negligible — not a realistic scenario for a profitable, fortress-balance-sheet franchise with a regulatory moat. The risk is overpaying, not insolvency.

Recent News & Events

Has the business environment changed recently? (Fact) Yes — favorably on operations, with new variables: (1) the destock recovery / re-acceleration (Q1-26 organic +15.3%, guide raised to +15–20% EPS); (2) the CEO transition (Green → Lagarde, ex-Thermo Fisher, eff 8/31/26) and Chair/CEO split; (3) a new $1B buyback; (4) the SmartDose 3.5mL divestiture to AbbVie (~mid-2026); (5) a May-2026 cyberattack (data exfiltrated, no material financial impact); (6) a Barclays upgrade to Overweight (PT $400, 6/9/26).

Significant acquisitions? (Fact) None — a divestiture (SmartDose 3.5mL) rather than an acquisition; West remains an organic builder.

Change in accounting policies? (Fact) No material policy change.

Recent changes — new markets, facilities, management? (Fact) The ~$1.3B 2022–25 HVP/GLP-1 capacity build (now moderating); the leadership transition (new CEO, new Chair, new CFO building a capital-allocation policy); continued Annex-1-driven HVP conversion.

APPENDIX B — Source Appendix

Sources supporting the research memo and diligence appendix. Primary sources prioritized over secondary. All web/market data accessed 2026-06-21 unless noted. Management commentary treated as hypothesis and validated against filings and external evidence.

A. Primary — SEC filings (EDGAR, CIK 0000105770)

1. Form 10-K, FY2025 — fiscal year ended 2025-12-31. Principal source: Item 1 (Business — segments, HVP, products/brands, customers, competition); Item 7 (MD&A — net-sales-by-segment, the gross-margin bridge, the destock/recovery narrative, adjusted-EPS reconciliation); segment footnote (Proprietary Products $2,492.1M / 81.1% / 26.4% OM / ~91% of segment profit; Contract-Manufactured $582.0M / 18.9% / 10.9% OM); customer concentration (top-10 47.6%; one customer 15.8% / $485.9M); end-market mix (biologics ~40%, pharma ~24%, generics ~17%); balance sheet (cash $791.3M, net cash ~$588M, goodwill $110M).
2. Form 10-K, FY2021–FY2024 — used for the five-year revenue/margin/EPS history (the COVID over-earn → destock arc: GM 41.5%→34.5%, EPS $8.67→$6.69), segment margins by year, and the capex/buyback record.
3. Form 10-Q, Q1-FY2026 — quarter ended 2026-03-31. Organic +15.3%, HVP components +22.6%, biologics +26%, price +3.5pts, op margin +350bps, adjusted EPS $2.13 (+47%); the guidance raise; the $1B buyback and Q1 repurchase ($298M).
4. Form 8-K, Q4-FY2025 earnings (EX-99.1, ~2026-02-12) — FY2025 results (revenue $3,074.1M, GAAP EPS $6.79, adjusted $7.29) and the initial FY2026 guide (adjusted EPS $7.85–8.20, organic 5–7%, capex $250–275M).
5. Form 8-K, Q1-FY2026 earnings (EX-99.1, ~2026-04-23) — the FY2026 guide raise to adjusted EPS $8.40–8.75 (+15–20%) and organic 7–9%.
6. Form 8-K, Item 5.02 (2026-06-01) — CEO transition: Eric Green retirement; Michel Lagarde appointed President & CEO effective 2026-08-31; Chair/CEO split (Robert Friel → Chair); Lagarde compensation terms.
7. Form 8-K (cyberattack disclosure, May 2026) — intrusion detected 2026-05-04, confirmed material 2026-05-07 (data exfiltrated, systems locked); operational by 2026-05-20; no material financial impact disclosed.
8. EDGAR XBRL company facts (companyfacts API) — multi-year revenue, margins, EPS, cash flow (OCF, capex, buybacks, dividends), balance sheet (cash, debt, goodwill, equity), shares. Accessed 2026-06-21.
9. DEF 14A (proxy) — executive compensation structure (PSUs = 50% of LTI on 3-year sales CAGR + ROIC, equally weighted; 2023–25 PSUs paid 41%); beneficial ownership; board/governance.
10. Form 3/4/5 (insider transactions) — 178 Form 4s parsed across the 5-year corpus; zero open-market purchases (code P); activity is grants, RSU/PSU vesting + tax withholding, and routine option-exercise-and-sell (CAO Winters, CHRO Favorite, April 2026).
11. Form 8-K series + SD (conflict minerals) — earnings 8-Ks, the SmartDose 3.5mL divestiture to AbbVie, buyback authorizations.

B. Primary — Company communications & transcripts

12. Q1-FY2026 earnings call transcript (~2026-04-23, via ROIC.ai) — guide raised to adjusted EPS $8.40–8.75; organic back to the 7–9% “long-term construct”; HVP components +22.6%; biologics +26%; margin path (“another 50 bps” H2 expansion); GLP-1 ~10% of sales; Annex-1 conversion; capex $250–275M; SmartDose 3.5mL sale to AbbVie (~mid-2026, ~$120–130M); the new $1B buyback.
13. Q4-FY2025 earnings call transcript (~2026-02-12, via ROIC.ai) — FY2025 results, the initial FY2026 guide, the GLP-1 framing (>30% oral penetration by 2030 base case; “orals expand the market”; “8 of 10 oral patients new to market”), Annex 1 (~6B components to upgrade, <15% done, 700+ projects, ~+200bps/yr).
14. Q3-FY2025 earnings call transcript (via ROIC.ai) — the destock-recovery confirmation (beat-and-raise quarters).
15. ROIC.ai financial database — income statement, balance sheet, cash flow, profitability ratios (ROIC trend 26.5%→15.4%, ROE), enterprise value (recomputed live at $327.95 — ROIC’s screen EV uses a stale ~$251 basis), valuation multiples, per-share data. Third-party aggregated; reconciled to filings. (Note: ROIC/yfinance mislabel operating cash flow as “free cash flow” — real FCF = OCF − capex, computed independently.)

C. Secondary — Market, factor, and price data (accessed 2026-06-21)

16. Five-year price history (split/dividend-adjusted OHLCV) — for the Stock Price Action event map; ~$465.70 ATH (Dec-2021) → $189.58 destock trough (Apr-2025) → $327.95 (2026-06-18); 52-week range ~$209–$335; ~30% below the 2021 peak.
17. News feeds — the Barclays Overweight upgrade (PT $310→$400, 6/9/26), the CEO-transition announcements (~6/1–6/2/26), the cyberattack disclosure, Morgan Stanley PT raise (5/29), and insider-form entries. Own-history valuation percentiles (P/E 44.2 / P/B 54.4 / P/S 56.2 / composite 51.6 — mid-range). Beta 0.705.
18. FactorsToday factor model — stock-info (beta 0.705, alpha −0.165, rs_12m +50.9%, rs_peak −29.6%); leaderboard (y1 Sharpe ~1.19 recovery, 3–5yr returns flat-to-negative — the COVID round-trip unwound); loadings (Life Sciences Tools & Services +0.46, low-beta tilt); factor-similar peers (STE, DHR, TMO, A, ILMN, IQV, TECH, MTD).
19. Public press / web — coverage of the Barclays upgrade, the CEO transition and Michel Lagarde’s background (Thermo Fisher EVP & COO via Patheon; JLL Partners; Philips; Vertex board), and the cybersecurity incident.

D. Peer / cohort comparables (public filings & market data)

20. Life-sciences-tools and pharma-packaging peer set — Repligen (RGEN, the closest bioprocessing-consumables destocking analog), Avantor (AVTR), Waters (WAT), Becton Dickinson (BDX, the prefilled-syringe peer and ROIC-quality contrast), Danaher (DHR), Thermo Fisher (TMO), Mettler-Toledo (MTD), Agilent (A), Steris (STE), Stevanato (STVN), AptarGroup (ATR) — public filings and market data used for the cohort valuation, the GLP-1/biologics framing, the destocking pattern, and the comp set.

E. Frameworks

23. Greenwald & Kahn, Competition Demystified — barriers-to-entry / moat-type taxonomy (demand captivity via switching costs; economies of scale); market-share-stability and ROIC tests; EPV.
24. Chancellor (ed.), Capital Returns (Marathon Asset Management) — supply-side capital-cycle analysis (the COVID build/destock whipsaw; the asset-growth signature of the ~$1.3B capacity build); high returns attract capital and mean-revert.

Note on confidence: figures sourced to EDGAR filings and EDGAR XBRL are treated as Fact. The through-cycle margin (~37–39% GM), the ROIC re-leverage, and the GLP-1/oral-substitution trajectory are Interpretation/Open Questions. The 15.8% customer’s identity is inferred (Interpretation), not disclosed. The FY2026 adjusted-EPS guide ($8.40–8.75, raised) is FACT per the Q1-FY2026 release.